Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...

Looking for new fast-food items to try? Expand your horizon with these new breakfast, lunch, and dinner meals from McDonald's ...

A gut microbe has been identified that mimics the effects of Ozempic to mitigate diabetes and obesity. Here's how to take ...

Brandee McKoon tried the traditional diets to lose weight but didn’t have much luck. The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually ...

Tori Allen says she’s thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more ...

In this Saturday edition of BI Today, we're talking about the end of a GLP-1 shortage, and Hollywood's awards season.

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...